Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSe basket trial

被引：0
|
作者：
Tomasini, P. [1 ]
Mazieres, J. [2 ]
Cropet, C. [3 ]
Troussard, X. G. [4 ]
Malka, D.
Ray-Coquard, I. L. [5 ,6 ]
Leboulleux, S. [7 ]
Flechon, A. [8 ]
Arnulf, B. [9 ]
Cancel, M. [10 ]
Bieche, I. [11 ]
Collot, S. [12 ]
Taieb, S. [13 ]
Garcia, G. [14 ]
Mandache, A-M. [15 ]
Colignon, N. [16 ]
Gavrel, M. [14 ]
Jimenez, M. [17 ]
Hoog-Labouret, N. [18 ]
Blay, J-Y. [6 ]
机构：
[1] Aix Marseille Univ, AP HM, Dept Multidisciplinary Oncol & Therapeut Innovat, Marseille, France
[2] Toulouse Univ Hosp, Thorac Oncol Dept, Toulouse, France
[3] Ctr Leon Berard, Direct Rech Clin & Innovat DRCI, Lyon, France
[4] CHU Caen Normandie, Hematol, Caen, France
[5] Gustave Roussy, Digest Oncol Dept, Villejuif, France
[6] Ctr Leon Berard, Med Oncol, Lyon, France
[7] Gustave Roussy, Med Nucl & Endocrine Oncol, Villejuif, France
[8] Ctr Leon Berard, Dept Urol Oncol, Lyon, France
[9] Hosp St Louis, APHP, Hematol, Paris, France
[10] CHU Bretonneau, Med Oncol, Tours, France
[11] Paris Descartes Univ, Dept Genet, Inst Curie, Paris, France
[12] CHU Toulouse, Radiol & Med Imagery, Hop Rangueil Larrey, Toulouse, France
[13] Oscar Lambret, Med Imagery, Lille, France
[14] Gustave Roussy, Med Imagery, Villejuif, France
[15] Ctr Leon Berard, Med Imagery, Lyon, France
[16] Hop St Antoine, APHP, Radiol, Paris, France
[17] UNICANCER, R&D Dept, Paris, France
[18] Natl Canc Inst, Res & Innovat, Boulogne, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.652
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
538P
引用
收藏
页码：S470 / S471
页数：2
相关论文
共 50 条
  • [1] Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: first results of the ACSE trial
    Blay, J-Y.
    Mazieres, J.
    Perol, D.
    Barlesi, F.
    Moro-Sibilot, D.
    Quere, G.
    Tredaniel, J.
    Troussard, X.
    Leboulleux, S.
    Malka, D.
    Flechon, A.
    Linassier, C.
    Ray-Coquard, I. L.
    Arnulf, B.
    Bieche, I.
    Ferretti, G.
    Nowak, F.
    Jimenez, M.
    Hoog-Labouret, N.
    Buzyn, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [2] Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSe Trial
    Mazieres, J.
    Montane, L.
    Barlesi, F.
    Coudert, B.
    Souquet, P. J.
    Otto, J.
    Gervais, R.
    Moro-Sibilot, D.
    Monnet, I.
    Brain, E.
    Huillard, O.
    Quere, G.
    Debieuvre, D.
    Fabre, E.
    Jaffro, M.
    Collot, S.
    Ferretti, G.
    Tiffon, C.
    Oukhatar, C. Mahier-Ait
    Blay, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S348 - S349
  • [3] BRAF V600 and Non-V600 Mutations in Chinese Lung Cancer
    Gao, Y.
    Chang, R.
    Huan, J.
    Xiao, X.
    Liu, Y.
    Zhou, Y.
    Li, L.
    Cheng, Y.
    Zhang, C.
    Dai, P.
    Guan, Y.
    Yi, X.
    Xia, X.
    Yang, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S911 - S911
  • [4] Immune biomarkers and response to checkpoint inhibition of BRAF(V600) and BRAF non-V600 altered lung cancers
    Murciano-Goroff, Yonina R.
    Pak, Terry
    Mondaca, Sebastian
    Flynn, Jessica R.
    Montecalvo, Joseph
    Rekhtman, Natasha
    Halpenny, Darragh
    Plodkowski, Andrew J.
    Wu, Stephanie L.
    Kris, Mark G.
    Paik, Paul K.
    Riely, Gregory J.
    Yu, Helena A.
    Rudin, Charles M.
    Hellmann, Matthew D.
    Land, Josiah D.
    Buie, Larry W.
    Heller, Glenn
    Lito, Piro
    Yaeger, Rona
    Drilon, Alexander
    Liu, Dazhi
    Li, Bob T.
    Offin, Michael
    [J]. BRITISH JOURNAL OF CANCER, 2022, 126 (06) : 889 - 898
  • [5] VEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION
    Haanen, J. B. A. G.
    Scholtens, A.
    Geukes, M.
    van Thienen, H.
    van Tinteren, H.
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [6] Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression
    Scholtens, A.
    Foppen, M. H. Geukes
    Blank, C. U.
    van Thienen, J. V.
    van Tinteren, H.
    Haanen, J. B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (05) : 642 - 652
  • [7] BRAF V600 and non-V600 mutations across distinct tumor types.
    Xie, Qichao
    Huan, Jiaojiao
    Zhao, Jun
    Chen, Yu
    Gao, Jie
    Liang, Naixin
    Zeng, Yu
    Liu, Lianke
    Xu, Chunwei
    Chen, Chen
    Guan, Yan-Fang
    Yang, Ling
    Xia, Xuefeng
    Yi, Xin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Melanoma Effectiveness of Vemurafenib on BRAF V600 Mutations
    Voos, Dunja
    [J]. AKTUELLE DERMATOLOGIE, 2014, 40 (11) : 434 - 434
  • [9] Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience
    Arance, A. M.
    Berrocal, A.
    Lopez-Martin, J. A.
    de la Cruz-Merino, L.
    Soriano, V.
    Martin Algarra, S.
    Alonso, L.
    Cerezuela, P.
    La Orden, B.
    Espinosa, E.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (11): : 1147 - 1157
  • [10] Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
    Hyman, David M.
    Puzanov, Igor
    Subbiah, Vivek
    Faris, Jason E.
    Chau, Ian
    Blay, Jean-Yves
    Wolf, Juergen
    Raje, Noopur S.
    Diamond, Eli L.
    Hollebecque, Antoine
    Gervais, Radj
    Elena Elez-Fernandez, Maria
    Italiano, Antoine
    Hofheinz, Ralf-Dieter
    Hidalgo, Manuel
    Chan, Emily
    Schuler, Martin
    Lasserre, Susan Frances
    Makrutzki, Martina
    Sirzen, Florin
    Veronese, Maria Luisa
    Tabernero, Josep
    Baselga, Jose
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 726 - 736
12345